Evaluating the Transition From Pediatric to Adult Care Among Adolescents With Chronic Granulomatous Disease
NCT02233036 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 33
Last updated 2018-04-05
Summary
Background:
People who get chronic illnesses as children are living longer. When they turn 18, they switch from pediatric care to adult care. This can be a difficult change. Chronic Granulomatous Disease (CGD) is an inherited disease. It causes long-term, repeated infections. People with CGD are usually diagnosed when they are very young children. Researchers want to find out more about how young people with CGD handle the change to adult care. What they learn may make this easier for people with CGD in the future.
Objective:
\- To identify what helped or hurt young adults with CGD as they went from pediatric to adult care.
Eligibility:
\- Adults with CGD who were 18 24 years old between January 2011 and February 2014.
Design:
* Participants will already be enrolled in NIH studies.
* Eligible people will get materials in the mail. They will get a letter with study information, an interview questionnaire, and an information sheet.
* Researchers will call participants 1 week after the packets are sent. They will talk about the study and find out if the person wants to join.
* An interview will be completed immediately or scheduled for the future. The interview will take about 45 minutes. The researcher will ask the participant about their disease. They will also ask about travel to NIH, being an outpatient or inpatient there, and legal documents.
* Researchers may contact the subjects again by phone if they need more information at any point during the study.
Conditions
- CGD
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Principal Investigators
-
Patricia R Driscoll, R.N. · National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility
- Min Age
- 18 Years
- Max Age
- 26 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-03-26
- Primary Completion
- 2016-01-11
- Completion
- 2017-01-10
Countries
- United States
Study Locations
More Related Trials
-
Gene Therapy for X-linked Chronic Granulomatous Disease (X-CGD)
NCT01855685 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease
NCT01147042 ·Status: TERMINATED ·Phase: PHASE4
-
Stem Cell Transplant Following Low-Intensity Chemotherapy to Treat Chronic Granulomatous Disease
NCT00001765 ·Status: COMPLETED ·Phase: PHASE1
-
Gene Therapy for Chronic Granulomatous Disease
NCT00394316 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood
NCT00001317 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)
NCT05600907 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Gene Therapy for X-linked Chronic Granulomatous Disease
NCT02757911 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Gene Therapy for X-linked Chronic Granulomatous Disease (CGD) in Children
NCT00927134 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease
NCT06325709 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Gene Therapy for Chronic Granulomatous Diseases - Long-term Follow-up
NCT00001476 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis
NCT00001761 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications
NCT05104723 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Lentiviral Gene Therapy for CGD
NCT03645486 ·Status: RECRUITING ·Phase: NA
-
Gene Therapy for X-CGD
NCT01906541 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
NCT07113743 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
Bronchial Inflammation in Patients With Severe Immune Deficiency Under Immunoglobulin Treatment
NCT01359384 ·Status: UNKNOWN
-
GLILD Diagnosed in Children and Young Adults With Common Variable Immunodeficiency
NCT03648567 ·Status: UNKNOWN
-
Lentiviral Gene Therapy for X-Linked Chronic Granulomatous Disease (X-CGD)
NCT01381003 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD
NCT02318082 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )
NCT06559176 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects
NCT03721965 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of the Frequency and of the Regulatory Function of Positive T Lymphocytes Dual CD4CD8aa (DP8a) Specific to a Bacteria of the Intestinal Microbiota (Faecalibacterium Prausnitzii) in Atopic Dermatitis, Asthma and Allergic Rhinitis
NCT02908360 ·Status: COMPLETED
-
Gene Therapy for Chronic Granulomatous Disease
NCT00564759 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)
NCT03395340 ·Status: TERMINATED ·Phase: PHASE2